TransMedics to Report Third Quarter 2020 Financial Results on November 4, 2020
TransMedics Group, Inc. (TMDX) will release its third-quarter financial results on November 4, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (TMDX) will release its third-quarter financial results on November 4, 2020, after market close. Following this, a conference call will be held at 4:30 p.m. ET. Investors can access the call by dialing (833) 378-1026 domestically or (236) 712-2500 internationally, using Conference ID: 1716957. TransMedics is a leader in organ transplant technologies, focusing on enhancing organ quality and increasing the utilization of donor organs for patients with end-stage organ failure.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was +0.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter after market close on Wednesday, November 4, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (833) 378-1026 for domestic callers or (236) 712-2500 for international callers, followed by Conference ID: 1716957. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.
View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2020-financial-results-on-november-4-2020-301157334.html
SOURCE TransMedics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.